Cargando…

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death

Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is currently being tested in phase II clinical trials. We herein aimed to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vetma, Vesna, Rožanc, Jan, Charles, Emilie M., Hellwig, Christian T., Alexopoulos, Leonidas G., Rehm, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841063/ https://www.ncbi.nlm.nih.gov/pubmed/28337955 http://dx.doi.org/10.3727/096504017X14897145996933

Ejemplares similares

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
por: Skoko, Josip, et al.
Publicado: (2018)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
por: Vetma, Vesna, et al.
Publicado: (2020)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018)

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
por: Perimenis, Philippos, et al.
Publicado: (2016)

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Synergistic inhibitory effects of the oxyresveratrol and dacarbazine combination against melanoma cells
por: Lee, Sang Gyu, et al.
Publicado: (2021)

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy
por: Xiong, Wei, et al.
Publicado: (2022)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l4sg8clhboi4e1v3s3cughlju7